abstract |
The present invention relates to a gene recombinant antibody which specifically reacts with human VEGF receptor Flt-1. Also, the present invention relates to a gene recombinant anti-human VEGF receptor Flt-1 antibody having an activity which neutralizes human Flt-1. Furthermore, it provides a method, a diagnostic agent and a therapeutic agent for treating diseases in which their morbid states progress by abnormal angiogenesis, such as proliferation or metastasis of solid tumors, arthritis in chronic rheumatoid arthritis, diabetic retinopathy, retinopathy of prematurity, psoriasis, and the like. |